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Abstract
Background: Several observations have suggested that anandamide, an endogenous cannabinoid ligand, plays an
important role in the modulation of cough sensitivity. However, it is unknown whether the anandamide
membrane transporter plays a role in this modulation. To test this hypothesis, we investigated the effects of
VDM11, an anandamide membrane transporter inhibitor, on capsaicin- and anandamide-induced cough.
Methods: The effect of VDM11, an anandamide membrane transporter inhibitor, on capsaicin- and anandamide-
induced cough in mice was examined.
Results: VDM11, at doses of 3–10 mg/kg subcutaneously, produced a dose-dependent antitussive effect. This
antitussive effect was antagonized by pretreatment with either intraperitoneal administration (3 mg/kg) or
inhalation (1 mg/ml) of SR141716A, a cannabinoid receptor (CB1) antagonist. However, intracerebroventricular
injection of SR141716A (0.03 mg/mouse) did not alter the effect of VDM11. Exposure of mice to a nebulized
solution of 10% DMSO, a vehicle of anandamide, induced a cough response (7.7 ± 0.6 coughs/3 min; n = 10).
Exposure of mice to a nebulized solution of anandamide, at concentrations of 0.03, 0.3 and 3 mg/ml, also produced
a cough response in a concentration-dependent manner. The number of coughs induced by low dose (0.03 mg/
ml) anandamide was significantly less than that of 10% DMSO. On the other hand, the number of coughs induced
by high dose (3 mg/ml) anandamide was significantly greater than that of 10% DMSO. When AM251 (1.8 mM), a
selective CB1 receptor antagonist, was given by aerosol for 4 min before inhalation of 0.03 mg/ml of anandamide,
the number of coughs was significantly increased to the level observed with 10% DMSO alone. When capsazepine
(0.3 mM), a selective TRPV1 receptor antagonist, was given via aerosol for 4 min before inhalation of 3 mg/ml of
anandamide, the number of coughs was significantly decreased to the levels observed with 10% DMSO alone. The
number of coughs induced by high dose (3 mg/ml) anandamide was significantly and dose-dependently reduced by
the pretreatment with VDM11.
Conclusion: These results suggest that anandamide, an endogenous cannabinoid ligand, may modulate cough
sensitivity and that anandamide transporters play an important role in this modulation. Furthermore, these
findings indicate that inhibition of the uptake of anandamide produced a potent antitussive effect and suggests that
the anandamide transporter may be a potential target for peripherally acting antitussive drugs.
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Background
Anandamide, an endogenous cannabinoid ligand, is an
ethanolamine amide of arachidonic acid that was first iso-
lated from porcine brain and has been proposed to be an
endogenous agonist of cannabinoid CB1 receptors [1].
On the other hand, several investigators have provided
pharmacological and molecular evidence that anandam-
ide is a full agonist at the vanilloid type 1 receptors (VR1,
also known as transient receptor potential vanilloid 1
(TRPV1)), which are the sites of action of the pungent
component of 'hot' red peppers, capsaicin [2]. We previ-
ously reported that WIN55141-2 ((R)-(+)-[2,3-dihydro-5-
methyl-3-[4-morpholinylmethyl] pyrrolo [1,2,3-de]-1,4-
benzoxazin-6-yl](1-naphthyl) methanone mesylate), a
high-affinity cannabinoid receptor agonist, produced a
dose-dependent inhibition of the number of capsaicin-
induced coughs in mice [3]. This antitussive effect of WIN
55212-2 was antagonized by pretreatment with N-(pipe-
ridin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide hydrochloride
(SR141716A), a cannabinoid CB1 receptor antagonist [3].
Therefore, we suggested that cannabinoid CB1 receptors
play an important role in mediating the antitussive effect
of cannabinoids [3]. Calignano et al [4] reported that
inhaled anandamide inhibited capsaicin-induced cough
and this effect was antagonized by pretreatment with
SR141716A, a cannabinoid CB1 antagonist in guinea
pigs. In contrast, Jia et al [5] reported that anandamide,
when given by aerosol, induced coughs in conscious
guinea pigs in a concentration-dependent manner. When
guinea pigs were pretreated with capsazepine, the number
of anandamide-induced coughs was significantly inhib-
ited [5]. These results suggest that anandamide may
inhibit and enhance capsaicin-induced cough through the
activation of cannabinoid CB1 receptors and TRPV1
receptors respectively. However, the details of the mecha-
nisms for the regulation of cough sensitivity by anandam-
ide are not yet well known. De Petrocellis et al [6]
demonstrated that anandamide increased the cytosolic
Ca2+  concentration in TRPV1-overexpressing HEK293
cells, and this effect was blocked by the TRPV1 antagonist
capsazepine. Furthermore, N-arachidonoyl-(2-methyl-4-
hydroxyphenyl) amine (VDM11), a selective anandamide
membrane transporter inhibitor, strongly inhibited the
effect of anandamide on the cytosolic Ca2+ concentration
in TRPV1-overexpressing HEK293 cells. Based on these
results, they suggested that anandamide may play a role as
an endovanilloid, which acts on the TRPV1 receptor at an
intracellular site [6]. Thus, it is reasonable to consider that
anandamide membrane transporters may play an impor-
tant role in the modulation of coughsensitivity via the reg-
ulation of C-fiber activities.
To test this hypothesis, we investigated the effects of
VDM11, an anandamide membrane transporter inhibitor,
on capsaicin- and anandamide-induced cough in mice.
Methods
Animals
Male ICR mice (Tokyo Animal Laboratory Inc., Tokyo,
Japan) weighing approximately 30 g were used. The ani-
mals had free access to food and water in an animal room,
which was maintained at 24 ± 1° with a 12-h light-dark
Dose-response relationship of the antitussive effect of  VDM11 in mice Figure 2
Dose-response relationship of the antitussive effect of 
VDM11 in mice. The antitussive effect of VDM11 was 
assessed 60 min after subcutaneous administration of 
VDM11. Each column represents the mean with S.E. of 10 
mice in each group. *P < 0.05 vs. vehicle-treated group.
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Time course of the antitussive effect of VDM11 (● ) on cap- saicin-induced coughs in mice Figure 1
Time course of the antitussive effect of VDM11 (● ) on cap-
saicin-induced coughs in mice. VDM11, at a dose of 10 mg/kg, 
was injected subcutaneously. Each point represents the mean 
with S.E. of 10 mice in each group. *P < 0.05 vs. respective 
vehicle (■  )-treated group.
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cycle. These studies were carried out in accordance with
the Declaration of Helsinki and/or with the guide for the
care and use of laboratory animals as adopted by the com-
mittee on the care and use of laboratory animals of Hoshi
University, accredited by the Ministry of Education, Cul-
ture, Sports, Science and Technology, Japan.
Antitussive assay
The cough reflex was induced as previously described[7].
Mice were exposed to a nebulized solution of capsaicin
(45 µM) under conscious and identical conditions using a
body plethysmograph. Capsaicin was dissolved to a con-
centration of 30 µg/ml in a 10% ethanol and 10% Tween
80 saline solution. The solution was diluted with saline.
Anandamide was dissolved in 10% DMSO. The mice were
exposed for 3 min to capsaicin or anandamide 60 min
before the administration of antitussive drugs to deter-
mine the frequency of control coughs (Cc). The mice were
also exposed for 3 min to capsaicin or anandamide 60
min after the administration of drugs. The number of
coughs produced per 3-min period of exposure to capsai-
cin was counted. The number of coughs produced after
administration of the drugs (Ct) was compared with the
number of control coughs (Cc). The antitussive effect was
expressed as the % inhibition of the number of control
coughs ((Cc - Ct)/Cc × 100).
Drugs
VDM11 and AM251 were purchased from TCRIS (Bristol,
UK). Anandamide and capsazepine was purchased from
Sigma-Aldrich Inc. (St. Lousi, MO, USA). SR141716A was
generously supplied by Sanofi Synthelabo Recherche
(Montpellier, France). VDM11 was dissolved in PBS/
Tween 80/ethanol (18:1:1 v/v) [8]. All other drugs were
dissolved in 10% DMSO. SR141716A was injected intra-
peritoneally 30 min after the administration of VDM11.
SR141716A was also administered by inhalation via an
aerosol for 4 min before the application of capsaicin.
SR141716A was injected intracerebroventricularly 10 min
before the application of capsaicin. Either capsazepine, a
selective TRPV1 receptor antagonist, or AM251, a selective
CB1 receptor antagonist, was also administered by aerosol
inhalation for 4 min before the application of anandam-
ide. VDM11 was also administered subcutaneously 60
min before the application of anandamide.
Statistics
Data are expressed as means ± S.E. The statistical signifi-
cance of differences was assessed by the Mann-Whitney U-
test to evaluate the antitussive effect. A level of probability
of 0.05 or less was considered significant.
Effects of inhaled or intracerebroventricularly administered  SR141716A on the antitussive effect of VDM11 Figure 4
Effects of inhaled or intracerebroventricularly administered 
SR141716A on the antitussive effect of VDM11. SR141716A 
aerosol was inhaled for 4 min at 60 min after the administra-
tion of VDM11 (just prior to the second application of capsa-
icin). SR141716A was injected intracerebroventricularly, 50 
min after VDM11 administration (10 min before the second 
application of capsaicin). The antitussive effect of VDM11 (10 
mg/kg) was assessed 60 min after subcutaneous administra-
tion. Each column represents the mean with S.E. of 10 mice 
in each group. *P < 0.05 vs. vehicle-treated group.
%
 
i
n
h
i
b
i
t
i
o
n
 
o
f
 
t
h
e
 
n
u
m
b
e
r
 
o
f
 
c
o
u
g
h
s
*
*
0
50
100
vehicle
  inhalation (mg/ml)
VDM11 (10mg/kg, s.c.)
1 0.3 0.1
 ( Pg, i.c.v.)
0.03
SR141716A
Effect of SR141716A on the antitussive effect of VDM11 Figure 3
Effect of SR141716A on the antitussive effect of VDM11. 
SR141716A was injected intraperitoneally 30 min after the 
administration of VDM11. The antitussive effect of VDM11 
(10 mg/kg) was assessed 60 min after administration. Each 
column represents the mean with S.E. of 7 mice in each 
group. *P < 0.05 vs. vehicle-treated group.
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Results
Antitussive effects of VDM11 on capsaicin-induced coughs
Exposure of control mice to a nebulized solution of cap-
saicin induced a reproducible cough response (17.3 ± 0.3
coughs/3 min; n = 101). Intraperitoneal injection of vehi-
cle had no significant effect on the reproducibility of
coughs over a period of 180 min after injection (Fig. 1).
Antitussive effects of VDM11 (10 mg/kg subcutaneously)
on capsaicin-induced cough reached a peak 60 min after
injection, gradually declined and then returned to the pre-
injection level 180 min after the administration of
VDM11 (Fig. 1). Thus, a time interval of 60 min after the
administration of VDM11 was chosen for experiments
designed to quantify its effect. As shown in Fig. 2, VDM11
at doses of 3, 6 and 10 mg/kg, subcutaneously, produced
a dose-dependent inhibition of the number of capsaicin-
induced coughs (Fig. 2). Exposure to capsaicin (45 µM) 60
min before and after the administration of vehicle
induced 16.6 ± 1.3 and 14.4 ± 1.2 coughs, respectively
(Fig. 2). The effect of vehicle on the number of capsaicin-
induced coughs was not significant.
Effects of SR141716A on the antitussive effects of VDM11
Pretreatment with SR141716A, a cannabinoid CB1 recep-
tor antagonist, at doses of 0.3, 1.0 and 3 mg/kg, intraperi-
toneally, dose-dependently antagonized the antitussive
effect of VDM11 (10 mg/kg, subcutaneously) (Fig. 3). Fur-
thermore, pretreatment with inhaled SR141716A at con-
centrations of 0.1, 0.3 and 1 mg/ml for 4 min also
concentration-dependently suppressed the antitussive
effect of VDM11 (10 mg/kg, subcutaneously) (Fig. 4).
However, intracerebroventricular pretreatment with
SR141716A, at a dose of 30 µg/mouse which was suffi-
cient to block the CB1 receptor [9], had no effect on the
antitussive effect of VDM11 (10 mg/kg, subcutaneously)
(Fig. 4).
Effect of anandamide on the cough reflex
As shown in Fig. 5, exposure of mice to a nebulized solu-
tion of 10% DMSO, a vehicle of anandamide, induced a
cough response (7.7 ± 0.6 coughs/3 min; n = 10). Expo-
sure of mice to a nebulized solution of anandamide, at
concentrations of 0.03, 0.3 and 3 mg/ml, also produced a
cough response in a concentration-dependent manner
(0.03 mg/ml, 5.3 ± 0.5 coughs/3 min, n = 10; 0.3 mg/ml,
8.1 ± 0.6 coughs/3 min; n = 10; 3 mg/ml, 14.3 ± 0.8
coughs/3 min; n = 10). The number of coughs induced by
low dose (0.03 mg/ml) anandamide wassignificantly less
than that of 10% DMSO. On the other hand, the number
of coughs induced by high dose (3 mg/ml) anandamide
was significantly greater than that of 10% DMSO.
Effect of AM251 on low dose (0 Figure 6
Effect of AM251 on low dose (0.03 mg/ml) anandamide-
induced reduction of the number of coughs. AM251 was 
administered via aerosol for 4 min before the inhalation of 
anandamide. Each column represents the mean with S.E. of 
10 mice in each group. *P < 0.05 vs. vehicle (10% DMSO)-
inhaled group.
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Effect of inhaled anandamide on the number of coughs Figure 5
Effect of inhaled anandamide on the number of coughs. The 
number of coughs produced during 3-min exposure periods 
was counted. Each column represents the mean with S.E. of 
10 mice in each group. *P < 0.05 vs. vehicle (10% DMSO)-
inhaled group.
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Effect of AM251 on low dose of anandamide-induced 
cough responses
When AM251 (1.8 mM), a selective CB1 receptor antago-
nist, was given by aerosol for 4 min before inhalation of
0.03 mg/ml of anandamide, the number of coughs was
significantly increased to the levels observed with 10%
DMSO alone (Fig. 6).
Effect of capsazepine and VDM11 on high dose of 
anandamide-induced cough responses
When capsazepine (0.3 mM), a selective TRPV1 receptor
antagonist, was given via aerosol for 4 min before inhala-
tion of 3 mg/ml of anandamide, the number of coughs
was significantly decreased to the levels observed with
10% DMSO alone.(Fig. 7A). Furthermore, as shown in
Fig. 7B, the number of coughs induced by high dose (3
mg/ml) anandamide was significantly and dose-depend-
ently reduced by the pretreatment with VDM11. Indeed,
when VDM11, at a dose of 3 mg/kg subcutaneously, was
used as pretreatment, the number of coughs was signifi-
cantly decreased to the level observed with 10% DMSO
alone.
Discussion
This study is the first to report that VDM11, a selective
anandamide membrane transporter inhibitor, dose-
dependently and significantly reduced the number of cap-
saicin-induced coughs. This antitussive effect of VDM11
was significantly antagonized by pretreatment with
SR141716A, a cannabinoid CB1 receptor antagonist.
These results suggest that the antitussive effect of VDM11
is mediated by the activation of cannabinoid CB1 recep-
tors. We previously demonstrated that WIN 55212-2, a
cannabinoid receptor agonist, had an antitussive effect
through the activation of cannabinoid CB1 receptors [3].
Furthermore, we also suggested that the antitussive effect
of WIN 55212-2 may depend mainly on central mecha-
nisms [3]. In the present study, we observed that the anti-
tussive effect of VDM11 was antagonized by systemic
intraperitoneal or inhaled pretreatment with SR141716A.
However, when SR141716A was injected intracerebroven-
tricularly, the antitussive effect of VDM11 was not antag-
onized. These results suggest that VDM11 exerts its
antitussive effect through an activation of peripheral CB1
receptors.
However, it is not reasonable to consider that VDM11
directly activates CB1 receptors. Giuffrida et al [10]
reported that systemic administration of AM404, an anan-
damide membrane transporter inhibitor, caused a gradual
increase in anandamide in rat plasma. Nemeth et al [11]
reported that a low concentration of anandamide inhib-
ited the release of substance P from peripheral capsaicin-
sensitive sensory nerve terminals via the activation of can-
nabinoid CB1 receptors. Recently, we reported that NS-
398, a selective cyclooxygenase-2 inhibitor, exerted
peripheral antitussive effects by inhibiting the release of
substance P from capsaicin-sensitive afferent C-fibers in
airways [12]. Thus, it seems likely that inhibition of the
release of substance P from capsaicin-sensitive sensory C-
fibers may cause inhibition of the cough reflex. It has been
reported that capsaicin binds to the cytosolic domain of
TRPV1 receptors because of its lipophilic nature [13]. Sub-
Effect of capsazepine (A) and VDM11 (B) on high dose (3 mg/ ml) anandamide-induced reduction of the number of coughs Figure 7
Effect of capsazepine (A) and VDM11 (B) on high dose (3 mg/
ml) anandamide-induced reduction of the number of coughs. 
Capsazepine was given by aerosol for 4 min before the inha-
lation of anandamide. The antitussive effect of VDM11 (10 
mg/kg) was assessed 60 min after subcutaneous administra-
tion. Each column represents the mean with S.E. of 10 mice 
in each group. *P < 0.05 vs. vehicle (10% DMSO)-inhaled 
group. #P < 0.05 vs. respective pre-value.
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stance P, which is contained in afferent C-fiber endings
within the airway epithelium and smooth muscle layer, is
released by activation of afferent C- fibers. Bonham et al
[14] reported that substance P stimulates rapidly adapting
receptors in guinea pigs. The stimulation of the rapidly
adapting receptors by substance P is a potential link
between the two airway defense systems, both of which
elicit bronchoconstriction, mucus secretion and cough.
Such a link, whereby C-fiber-receptor stimulation lead to
the release of substance P and the subsequent stimulation
of rapidly adapting receptors, has been previously pro-
posed to explain the overlap of stimuli and reflex effects
of both afferent systems [15]. Namely, that activation of
TRPV1 receptors by capsaicin causes the release of sub-
stance P and the subsequent stimulation of rapidly adapt-
ing receptors, which may enhance cough reflexes. Based
on these findings, it is possible that VDM11 accumulates
endogenous anandamide, which results in the stimula-
tion of cannabinoid CB1 receptors and the subsequent
inhibition of substance P release from capsaicin-nensitive
afferent C-fibers, which may produce the antitussive
effect.
The above mentioned possibilities are further supported
by the results of the present study. We observed that anan-
damide alone produced a biphasic modulation of the
cough reflex. Indeed, the number of coughs induced by
the inhalation of lower dose of anandamide (0.03 mg/ml)
was significantly less than those induced by the inhalation
of vehicle alone. On the other hand, the number of
coughs induced by the inhalation of higher doses of anan-
damide (3 mg/ml) was significantly greater than those
induced by the inhalation of vehicle alone. We also
observed that when the animals were pretreated with
AM251, a selective CB1 receptor antagonist, the number
of coughs induced by the inhalation of lower dose of
anandamide (0.03 mg/ml) was increased to the level of
those induced by the inhalation of vehicle alone. This
result suggests that activation of CB1 receptors by ananda-
mide causes an inhibitory modulation of the cough reflex.
Furthermore, it is possible that higher doses of anandam-
ide may cause the activation of the cytosolic domain of
TRPV1 receptors, since anandamide-induced enhance-
ment of the number of coughs was abolished by pretreat-
ment with either capsazepine, a selective TRPV1 receptor
antagonist, or VDM11.
In conclusion, the present results suggest that anandam-
ide, an endogenous cannabinoid ligand, may modulate
cough sensitivity and anandamide transporters play an
important role in this modulation. Furthermore, these
findings indicate that inhibition of the uptake of ananda-
mide produced a potent antitussive effect and suggest that
the anandamide transporter is a potential target for
peripherally acting antitussive drugs.
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